Continuing Medical Education Information Faculty Disclosure Summary

Course Name: RheumNow Live 2019 March 22-24, 2019

Course Learning Objectives:

At the end of this course, participants should be able to:

1. Demonstrate increased knowledge regarding the pathogenic mechanisms, genetics and immunologic processes underlying rheumatic, inflammatory and immunologic disorders

2. Recognize the importance of early and aggressive management of inflammatory and autoimmune disease

3. Discuss the mechanisms of action of various drugs and immunomodulatory agents commonly used in rheumatologic care and advocated by current guidelines

4. Explain the range of adverse events that may accompany the use of immunomodulatory agents and know how to best avoid, prevent and monitor for drug safety

5. Point out the updated and new disease management guidelines, diagnostic classification criteria and outcome measures necessary for the optimal care of rheumatic disease patients

6. Distinguish the lifestyle modifications, ancillary services, orthopedic management, and other therapies necessary to best manage both the disease and comorbidities attendant to chronic inflammatory and immunologically driven damage.

7. Discuss the importance of shared decision making, effective clinician-patient communications accurate appraisal of scientific information in quest to deliver optimal medical care.

8. Recognize major issues and advances related to the management of patients with rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis and the patient in need of orthopedic evaluation and surgery.

In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:

Planning Committee Member

John J. Cush, MD Clinical Investigator: AbbVie, Astra- Zeneca, Aurinia, BMS, Genentech, Novartis, Pfizer Advisory and Consultant: AbbVie, Amgen, BMS, Boehringer-Ingelheim, Celgene, Genentech, Horizon, Lilly, Novartis, UCB

Arthur Kavanaugh, MD Grant/Research Support: Amgen, Abbvie, Eli Lilly, Novartis, Pfizer

Nicole Gomez- No Relevant Relationships

Barb Forney – Compliance – No Relevant Relationships Program Manager Office of Continuing Medical Education University of Cincinnati

Bruce Gebhardt, MD – No Relevant Relationships University of Cincinnati College of Medicine Family Medicine - Professor

Speakers

Buzz Burkhead, MD Nothing to Disclose

Leonard Calabrese, MD Consultant: Amgen, Abbive, BMS, Genentech, UCB, Horizon, Sanofi-Genzyme, Crescendo, GSK, Pfizer, Lilly, Gielad

Philip Conaghan, MD Speakers Bureau: Abbvie, BMS, Novartis, Pfizer

Doruk Erkan, MD Clinical Research: GSK Research Consultant: Momenta, Celgene, Ablynx

Madelaine Feldman, MD Advisory Board: Merck Honoraria Recipient: Lilly

Richard Furie, MD Research Support:

Amgen, AstraZeneca, BiogenIdec, BMS, Boehringer-Ingelheim, Boston Pharmaceuticals, Celgene, Eli Lilly, Genentech/Roche, GSK, Kezar Life Sciences, Medimmune, Nektar Therapeutics, Takeda, UCB **Consultant**:

Amgen, AstraZeneca, BiogenIdec, BMS, Boehringer-Ingelheim, Boston Pharmaceuticals, Celgene, Eli Lilly, EMD Merck Serono, Genentech/Roche, Glenmark, GSK, Janssen, Medimmune, Nektar Therapeutics, Novartis, Takeda, UCB

Investigator:

Amgen, AstraZeneca, BiogenIdec, BMS, Boehringer-Ingelheim, Boston Pharmaceuticals, Celgene, Eli Lilly, EMD Merck Serono, Genentech/Roche, GSK, Medimmune, Nektar Therapeutics, Takeda, UCB

Michael Holers, MD Research Grant: Janssen Consultant: Celgene Honoraria: Novartis Elaine Husni, MD

Consultant: Abbvie, Pfizer, Janssen, Novartis, Lilly, Genentech, Amgen, UCB, Sanofi **Advisory Board:** Abbvie, Pfizer, Janssen, Novartis, Lilly, Genentech, Amgen, UCB, Sanofi

Ken Kalunian, MD Nothing to disclose

Carol Langford, MD Research Grant: Genentech, BMS, GSK, ChemoCentryx, Consultant: Abbvie, BMS, AstraZeneca

Craig Leonardi, MD Consultant, Advisory Board: Abbvie, Amgen, Boehringer-Ingelheim, Dermira, Eli Lilly, Janssen, Leo, Pfizer, Sandoz, and VC Band Vitae. Investigator:

Actavis, Abbvie, Amgen, Allergan, Boehringer-Ingelheim, Celgene, Coherus, Cellceutix, Corrona, Dermira, Eli Lilly, Galderma, Glenmark, Janssen, LeoPharma, Merck ,Novartis, Novella, Pfizer, Sandoz, Sienna, Stiefel, Wyeth.

Speaker: Abbvie, Celgene, Novartis, Sun Pharmaceuticals, Eli Lilly.

Kenneth B. Mathis, MD Royaltis: Zimmer/Biomet

Eric Matteson, MD Nothing to disclose

Paul Monach, MD CME: MedScape, NACCME Clinical trials/Investigator: GSK, BMS, ChemoCentryx Ivan Oransky, MD Employee: MedScape

John O'Shea, MD Advisory Board: Us Patent, Pfizer Research: Us Patent, Pfizer

Ted Pincus, MD Please reference disclosure slide at start of presentation

John Reveille, MD Research Grant: Janssen Consultant: Novartis, Lilly, Pfizer

Eric Ruderman, MD Advisory Board: Corrona Consultant: Amgen, GSK, Lilly, Pfizer, Novartis Review Panel: Abbvie, Janssen

Lisa Sammaritano, MD Nothing to disclose

Georg Schett, MD Please reference disclosure slide at start of presentation

Philip Seo, MD

Nothing to disclose

Ron Van Vollenhoven, MD Research Support and Grants: BMS, GSK, Lilly, Pfizer, Roche, UCB Consultancy/Honoraria: AbbVie, Biotest, BMS, Celgene, GSK, Janssen, Lilly, Pfizer, Servier, UCB

Michael Weinblatt, MD Consulting: Abbvie, Amgen, BMS, Canfite, Corona, Crescendo, GSK, Gilead, Horizon, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Scipher Set Point *Stockholder:* Canfite, Lycera, Scipher, Inmedix *Research Grants:*

Fred Wolfe, MD

Nothing to disclose

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Learner Assurance Statement

The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Advances in Cosmetic and Medical Dermatology.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credits \mathcal{M} . Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclaimer Statement

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

Commercial Acknowledgement

We gratefully acknowledge the following companies for their educational grant(s) in support of this educational activity.

AbbVie Inc., Celgene, GSK, Janssen Biotech, Inc., Myriad